Strong Buy - Cancer Genetics (NASDAQ:CGIX) Stock Rating Upgraded by ValuEngine
ValuEngine upgraded shares of Cancer Genetics (NASDAQ:CGIX) from a buy rating to a strong-buy rating in a report published on Saturday, ValuEngine reports.
Shares of CGIX opened at $5.24 on Friday. The business’s 50-day moving average is $2.20 and its two-hundred day moving average is $0.66. The company has a quick ratio of 0.99, a current ratio of 0.99 and a debt-to-equity ratio of 0.02. Cancer Genetics has a fifty-two week low of $2.00 and a fifty-two week high of $20.70.
Get Cancer Genetics alerts:
A hedge fund recently raised its stake in Cancer Genetics stock. Renaissance Technologies LLC boosted its stake in shares of Cancer Genetics Inc (NASDAQ:CGIX) by 38.4% during the 2nd quarter, according to its most recent filing with the SEC. The firm owned 2,777,125 shares of the medical research company’s stock after purchasing an additional 769,896 shares during the period. Renaissance Technologies LLC owned approximately 4.80% of Cancer Genetics worth $453,000 at the end of the most recent quarter.
About Cancer Genetics
Cancer Genetics, Inc develops, commercializes, and provides molecular and biomarker-based tests and services in the United States, Europe, and Asia. Its tests enable physicians to personalize the clinical management of each individual patient by providing genomic information to diagnose, monitor, and inform cancer treatment; and enable biotech and pharmaceutical companies involved in oncology and immuno-oncology trials to select candidate populations and reduce adverse drug reactions by providing information regarding genomic factors influencing subject responses to therapeutics.
